Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Atara Biotherapeutics, Inc. (ATRA) had Normalized Income after Taxes of $-85.40M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$128.94M |
|
$-85.40M |
|
$21.01M |
|
$107.93M |
|
$212.38M |
|
$-83.44M |
|
$-1.98M |
|
$-85.42M |
|
$-85.42M |
|
$-85.40M |
|
$-85.40M |
|
$-85.40M |
|
|
Normalized Income after Taxes |
$-85.40M |
$-83.44M |
|
$-78.63M |
|
7.49M |
|
7.49M |
|
$-11.41 |
|
$-11.41 |
|
| Balance Sheet Financials | |
$64.89M |
|
$1.29M |
|
$44.20M |
|
$109.10M |
|
$134.57M |
|
-- |
|
$71.81M |
|
$206.38M |
|
$-97.28M |
|
$-97.28M |
|
$-97.28M |
|
5.86M |
|
| Cash Flow Statement Financials | |
$-68.72M |
|
$8.62M |
|
$59.28M |
|
$25.99M |
|
$25.18M |
|
$-0.81M |
|
$27.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.48 |
|
-- |
|
-- |
|
-- |
|
-- |
|
83.71% |
|
-64.71% |
|
-64.71% |
|
-60.98% |
|
-66.24% |
|
-66.23% |
|
$-68.96M |
|
-- |
|
-- |
|
-- |
|
1.18 |
|
1.97 |
|
87.00 |
|
4.20 |
|
87.79% |
|
87.79% |
|
-78.28% |
|
87.79% |
|
$-16.60 |
|
$-9.21 |
|
$-9.18 |
|